Molecular Partners Ag Stock Price Patterns
| MOLN Stock | USD 4.70 0.09 1.95% |
Momentum 45
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (0.34) | EPS Estimate Current Year (1.53) | EPS Estimate Next Year (1.04) | Wall Street Target Price 11.9422 | EPS Estimate Current Quarter (0.37) |
Using Molecular Partners hype-based prediction, you can estimate the value of Molecular Partners AG from the perspective of Molecular Partners response to recently generated media hype and the effects of current headlines on its competitors.
Molecular Partners Hype to Price Pattern
Investor biases related to Molecular Partners' public news can be used to forecast risks associated with an investment in Molecular. The trend in average sentiment can be used to explain how an investor holding Molecular can time the market purely based on public headlines and social activities around Molecular Partners AG. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Molecular Partners' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Molecular Partners.
The fear of missing out, i.e., FOMO, can cause potential investors in Molecular Partners to buy its stock at a price that has no basis in reality. In that case, they are not buying Molecular because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Molecular Partners after-hype prediction price | USD 4.76 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Molecular | Build AI portfolio with Molecular Stock |
Molecular Partners After-Hype Price Density Analysis
As far as predicting the price of Molecular Partners at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Molecular Partners or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Molecular Partners, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Molecular Partners Estimiated After-Hype Price Volatility
In the context of predicting Molecular Partners' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Molecular Partners' historical news coverage. Molecular Partners' after-hype downside and upside margins for the prediction period are 1.69 and 7.83, respectively. We have considered Molecular Partners' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Molecular Partners is slightly risky at this time. Analysis and calculation of next after-hype price of Molecular Partners is based on 3 months time horizon.
Molecular Partners Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Molecular Partners is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Molecular Partners backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Molecular Partners, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.21 | 3.07 | 0.06 | 0.00 | 7 Events / Month | 7 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
4.70 | 4.76 | 1.28 |
|
Molecular Partners Hype Timeline
Molecular Partners is now traded for 4.70. The entity has historical hype elasticity of 0.06, and average elasticity to hype of competition of 0.0. Molecular is expected to increase in value after the next headline, with the price projected to jump to 4.76 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 1.28%, whereas the daily expected return is now at 0.21%. The volatility of related hype on Molecular Partners is about 76750.0%, with the expected price after the next announcement by competition of 4.70. The company reported the previous year's revenue of 4.97 M. Net Loss for the year was (54.04 M) with loss before overhead, payroll, taxes, and interest of (40.4 M). Given the investment horizon of 90 days the next expected press release will be in about 7 days. Check out Molecular Partners Basic Forecasting Models to cross-verify your projections.Molecular Partners Related Hype Analysis
Having access to credible news sources related to Molecular Partners' direct competition is more important than ever and may enhance your ability to predict Molecular Partners' future price movements. Getting to know how Molecular Partners' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Molecular Partners may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| APLT | Applied Therapeutics | 0.00 | 9 per month | 0.00 | (0.20) | 10.00 | (15.73) | 83.66 | |
| ELTX | Elicio Therapeutics | (0.30) | 10 per month | 0.00 | (0.05) | 5.76 | (4.34) | 21.98 | |
| CRBP | Corbus Pharmaceuticals Holding | (0.11) | 11 per month | 0.00 | (0.19) | 5.95 | (7.74) | 16.04 | |
| MIST | Milestone Pharmaceuticals | 0.04 | 8 per month | 0.00 | (0.03) | 6.15 | (6.38) | 34.31 | |
| CRDF | Cardiff Oncology | 0.12 | 8 per month | 0.00 | (0.07) | 9.28 | (6.82) | 45.59 | |
| RANI | Rani Therapeutics Holdings | 0.02 | 8 per month | 0.00 | (0.15) | 9.28 | (8.96) | 26.23 | |
| NKTX | Nkarta Inc | 0.04 | 6 per month | 3.35 | (0.02) | 5.21 | (5.96) | 17.73 | |
| PEPG | PepGen | 0.18 | 7 per month | 6.23 | 0.01 | 10.14 | (10.09) | 27.05 | |
| SAVA | Cassava Sciences | (0.12) | 7 per month | 0.00 | (0.11) | 9.05 | (7.56) | 35.02 | |
| ALEC | Alector | 0.09 | 7 per month | 3.63 | 0.11 | 5.63 | (7.32) | 18.01 |
Molecular Partners Additional Predictive Modules
Most predictive techniques to examine Molecular price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Molecular using various technical indicators. When you analyze Molecular charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Molecular Partners Predictive Indicators
The successful prediction of Molecular Partners stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Molecular Partners AG, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Molecular Partners based on analysis of Molecular Partners hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Molecular Partners's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Molecular Partners's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 90.5 | 81.45 | 73.3 | 69.64 | PTB Ratio | 0.64 | 0.98 | 1.12 | 1.07 |
Pair Trading with Molecular Partners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Molecular Partners Basic Forecasting Models to cross-verify your projections. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Biotechnology sector continue expanding? Could Molecular diversify its offerings? Factors like these will boost the valuation of Molecular Partners. Expected growth trajectory for Molecular significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Molecular Partners data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Molecular Partners' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Molecular Partners represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Molecular Partners' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.